VIVE (Viveve Medical) 5-Year EBITDA Growth Rate: 0.00% (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIVE Viveve Medical Inc VIVE
12 GF Score
Price $0.00
View Full Analysis

What is Viveve Medical 5-Year EBITDA Growth Rate?

Viveve Medical VIVE 12 5-Year EBITDA Growth Rate is 0.00% as of Sep. 2022. GuruFocus rates VIVE with a GF Score™ of 12/100.

Viveve Medical's EBITDA per Share for the three months ended in Sep. 2022 was $-0.42.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Viveve Medical  (OTCPK:VIVE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Viveve Medical 5-Year EBITDA Growth Rate Related Terms

VIVE vs NNMX, LHDXQ, ABT: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Viveve Medical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viveve Medical 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Viveve Medical's 5-Year EBITDA Growth Rate falls into.


VIVE
12GF Score
Viveve Medical Inc VIVE
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viveve Medical 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Viveve Medical (VIVE) has a 5-Year EBITDA Growth Rate of 0.00% as of Sep. 2022. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Viveve Medical and its competitors.
Is Viveve Medical's 5-Year EBITDA Growth Rate too high?
Viveve Medical's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Viveve Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Viveve Medical's 5-Year EBITDA Growth Rate compare to NNMX and LHDXQ?
Viveve Medical's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Viveve Medical and its competitors. Viveve Medical's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viveve Medical stock overvalued right now?
Viveve Medical (VIVE) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Viveve Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Viveve Medical (VIVE), the current 5-Year EBITDA Growth Rate is 0.00% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viveve Medical Business Description

Address 345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
12GF Score

Get the complete analysis for VIVE

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price